Systemic lupus erythematosus diagnosis and management

SLE presents many challenges for clinicians. The onset of disease may be insidious, with many different symptoms and signs, making early and accurate diagnosis challenging. Tests for SLE in the early stages lack specificity; those that are useful later often appear only after organ damage is manifest. Disease patterns are highly variable; flares are not predictable and not always associated with biomarkers. Children with SLE may have severe disease and present special management issues. Older SLE patients have complicating co-morbid conditions. Therapeutic interventions have improved over recent decades, but available drugs do not adequately control disease in many patients, and successful outcomes are limited by off-target effects; some of these become manifest with longer duration of treatment, now in part revealed by improved rates of survival. Despite all of these challenges, advances in understanding the biological basis of SLE have translated into more effective approaches to patient care. This review considers the current state of SLE diagnosis and management, with a focus on new approaches and anticipated advances.

[1]  Y. Levy,et al.  The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide , 2009, Annals of the rheumatic diseases.

[2]  D. Gladman,et al.  Neuropsychiatric lupus: the prevalence and autoantibody associations depend on the definition: results from the 1000 faces of lupus cohort. , 2012, Seminars in arthritis and rheumatism.

[3]  J. Yazdany,et al.  Medication Nonadherence Is Associated With Increased Subsequent Acute Care Utilization Among Medicaid Beneficiaries With Systemic Lupus Erythematosus , 2015, Arthritis care & research.

[4]  D. Gladman,et al.  Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. , 2008, Arthritis and rheumatism.

[5]  B. Parker,et al.  SLE and metabolic syndrome , 2013, Lupus.

[6]  G. Hughes,et al.  Central nervous system involvement in the antiphospholipid (Hughes) syndrome. , 2003, Rheumatology.

[7]  F. Houssiau,et al.  Thirty years of cyclophosphamide: assessing the evidence , 2007, Lupus.

[8]  R. Tattersall The MAGICC and practical approach to rheumatology transition. , 2012, British journal of hospital medicine.

[9]  R. Sakthiswary,et al.  Methotrexate in systemic lupus erythematosus: a systematic review of its efficacy , 2014, Lupus.

[10]  A D GUNN,et al.  Case of Anaphylaxis after Anaesthesia , 1943, British medical journal.

[11]  Hui Luo,et al.  Autoantigen Microarray for High-throughput Autoantibody Profiling in Systemic Lupus Erythematosus , 2015, Genom. Proteom. Bioinform..

[12]  K. Kalunian,et al.  Sifalimumab, an anti-interferon-α monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study , 2016, Annals of the rheumatic diseases.

[13]  C. Gordon,et al.  Malignancies in systemic lupus erythematosus , 2013, Systemic Lupus Erythematosus.

[14]  D. Gladman,et al.  Prolonged Serologically Active Clinically Quiescent Systemic Lupus Erythematosus: Frequency and Outcome , 2010, The Journal of Rheumatology.

[15]  M. Petri,et al.  Unmet medical needs in systemic lupus erythematosus , 2012, Arthritis Research & Therapy.

[16]  D. Furst,et al.  American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid‐induced osteoporosis , 2010, Arthritis care & research.

[17]  E. Ginzler,et al.  Long-term maintenance therapy with azathioprine in systemic lupus erythematosus. , 1975, Arthritis and rheumatism.

[18]  L. Trupin,et al.  Reasons for failure to receive pneumococcal and influenza vaccinations among immunosuppressed patients with systemic lupus erythematosus. , 2015, Seminars in arthritis and rheumatism.

[19]  Anisur Rahman,et al.  Efficacy and Safety of Nonbiologic Immunosuppressants in the Treatment of Nonrenal Systemic Lupus Erythematosus: A Systematic Review , 2013, Arthritis care & research.

[20]  D. Isenberg,et al.  DNA-damaging autoantibodies and cancer: the lupus butterfly theory , 2016, Nature Reviews Rheumatology.

[21]  M. Hudson,et al.  Treatment Algorithms in Systemic Lupus Erythematosus , 2015, Arthritis care & research.

[22]  G. Tsokos,et al.  Systemic lupus erythematosus. , 2011, The New England journal of medicine.

[23]  J. Piette,et al.  Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases. , 2002, The Journal of rheumatology.

[24]  E. Morand,et al.  Vitamin D and systemic lupus erythematosus: continued evolution , 2015, International journal of rheumatic diseases.

[25]  D. Isenberg,et al.  How to monitor SLE in routine clinical practice , 2005, Annals of the rheumatic diseases.

[26]  J. Branco,et al.  Classification of Systemic Lupus Erythematosus: Systemic Lupus International Collaborating Clinics Versus American College of Rheumatology Criteria. A Comparative Study of 2,055 Patients From a Real‐Life, International Systemic Lupus Erythematosus Cohort , 2015, Arthritis care & research.

[27]  R. Glassock,et al.  Renal disease : classification and atlas , 1987 .

[28]  J. Reveille,et al.  Possible protective effect of hydroxychloroquine on delaying the occurrence of integument damage in lupus: LXXI, data from a multiethnic cohort , 2010, Arthritis care & research.

[29]  M. Klein-Gitelman,et al.  International Consensus for Provisions of Quality‐Driven Care in Childhood‐Onset Systemic Lupus Erythematosus , 2013, Arthritis care & research.

[30]  Lee Hebert,et al.  The classification of glomerulonephritis in systemic lupus erythematosus revisited. , 2004, Journal of the American Society of Nephrology : JASN.

[31]  C. Gordon,et al.  Development of quality indicators to evaluate the monitoring of SLE patients in routine clinical practice. , 2011, Autoimmunity reviews.

[32]  T. Luger,et al.  Revised Cutaneous Lupus Erythematosus Disease Area and Severity Index (RCLASI): a modified outcome instrument for cutaneous lupus erythematosus , 2010, The British journal of dermatology.

[33]  D. Gladman,et al.  Prolonged Clinical Remission in Patients with Systemic Lupus Erythematosus , 2014, The Journal of Rheumatology.

[34]  L. Punzi,et al.  Disease activity patterns in a monocentric cohort of SLE patients: a seven-year follow-up study. , 2012, Clinical and experimental rheumatology.

[35]  J. Buyon,et al.  The clinical spectrum of autoimmune congenital heart block , 2015, Nature Reviews Rheumatology.

[36]  D. Gladman,et al.  Clinically active serologically quiescent systemic lupus erythematosus. , 2003, The Journal of rheumatology.

[37]  S. Grando,et al.  Efficacy of Intravenous Immunoglobulin Monotherapy in Patients with Cutaneous Lupus Erythematosus: Results of Proof-of-Concept Study , 2015, Dermatology reports.

[38]  What investigations are needed to optimally monitor for malignancies in SLE? , 2015, Lupus.

[39]  D. Isenberg,et al.  B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design , 2013, Arthritis Research & Therapy.

[40]  S. Ozen,et al.  Performance of the new SLICC classification criteria in childhood systemic lupus erythematosus: a multicentre study. , 2014, Clinical and experimental rheumatology.

[41]  K. Kalunian,et al.  Comparison of hydroxychloroquine and placebo in the treatment of the arthropathy of mild systemic lupus erythematosus. , 1994, The Journal of rheumatology.

[42]  Jinoos Yazdany,et al.  American College of Rheumatology guidelines for screening, treatment, and management of lupus nephritis , 2012, Arthritis care & research.

[43]  M. Marmor,et al.  Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). , 2016, Ophthalmology.

[44]  Gerald McGwin,et al.  Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. , 2012, Arthritis and rheumatism.

[45]  D. Gladman,et al.  Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period , 2012, Arthritis care & research.

[46]  M. Son,et al.  Disease activity and transition outcomes in a childhood-onset systemic lupus erythematosus cohort , 2016, Lupus.

[47]  M. Petri,et al.  Improvements in health-related quality of life with belimumab, a B-lymphocyte stimulator-specific inhibitor, in patients with autoantibody-positive systemic lupus erythematosus from the randomised controlled BLISS trials , 2013, Annals of the rheumatic diseases.

[48]  I. Bruce,et al.  Treat-to-target in systemic lupus erythematosus: recommendations from an international task force , 2014, Annals of the rheumatic diseases.

[49]  J. Stockman Mycophenolate versus Azathioprine as Maintenance Therapy for Lupus Nephritis , 2013 .

[50]  K. Legault,et al.  Successful treatment of recurrent pleural and pericardial effusions with tocilizumab in a patient with systemic lupus erythematous , 2016, BMJ Case Reports.

[51]  A. Kuhn,et al.  The classification and diagnosis of cutaneous lupus erythematosus. , 2014, Journal of autoimmunity.

[52]  N. Wulffraat,et al.  HPV infection and vaccination in Systemic Lupus Erythematosus patients: what we really should know , 2016, Pediatric Rheumatology.

[53]  M. Petri,et al.  Managing lupus patients during pregnancy. , 2013, Best practice & research. Clinical rheumatology.

[54]  Y. Chan,et al.  Thiopurine S-methyltransferase activity in three major Asian populations: a population-based study in Singapore , 2008, European Journal of Clinical Pharmacology.

[55]  J. Callen Management of antimalarial-refractory cutaneous lupus erythematosus , 1997, Lupus.

[56]  K. Kirou,et al.  What Causes Lupus Flares? , 2016, Current Rheumatology Reports.

[57]  A. Robinson,et al.  Systemic lupus erythematosus, bone health, and osteoporosis , 2015, Current opinion in endocrinology, diabetes, and obesity.

[58]  BJ Parker,et al.  High dose methylprednisolone therapy for the treatment of severe systemic lupus erythematosus , 2007, Lupus.

[59]  J. Harley,et al.  Evidence of Dynamically Dysregulated Gene Expression Pathways in Hyperresponsive B Cells from African American Lupus Patients , 2013, PloS one.

[60]  E. Yelin,et al.  A quality indicator set for systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[61]  L. Lennard Implementation of TPMT testing. , 2014, British journal of clinical pharmacology.

[62]  G. Baehr,et al.  Use of cortisone and adrenocorticotropic hormone in acute disseminated lupus erythematosus. , 1950, A.M.A. archives of internal medicine.

[63]  Mimi Y. Kim,et al.  Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. , 2005, The New England journal of medicine.

[64]  S. Bernatsky,et al.  Malignancies in systemic lupus erythematosus: a 2015 update , 2015, Current opinion in rheumatology.

[65]  J. Stevenson,et al.  Bisphosphonate drug holidays – when, why and for how long? , 2015, Climacteric : the journal of the International Menopause Society.

[66]  L. Lightstone Minimising steroids in lupus nephritis – will B cell depletion pave the way? , 2013, Lupus.

[67]  T. Chan Treatment of severe lupus nephritis: the new horizon , 2015, Nature Reviews Nephrology.

[68]  P H Plotz,et al.  Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. , 1986, The New England journal of medicine.

[69]  R. Fischer-Betz,et al.  The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation , 2016, Annals of the rheumatic diseases.

[70]  J. Gómez-Reino,et al.  Adipokines, Metabolic Syndrome and Rheumatic Diseases , 2014, Journal of immunology research.

[71]  Y. Levy,et al.  Early response to immunosuppressive therapy predicts good renal outcome in lupus nephritis: lessons from long-term followup of patients in the Euro-Lupus Nephritis Trial. , 2004, Arthritis and rheumatism.

[72]  M. Hochberg,et al.  Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. , 1997, Arthritis and rheumatism.

[73]  M. Haust,et al.  Development of a Core Set Questionnaire by the European Society of Cutaneous Lupus Erythematosus (EUSCLE). , 2009, Autoimmunity reviews.

[74]  M. McClung Controversies in osteoporosis management: concerns about bisphosphonates and when are "drug holidays" required? , 2013, Clinical obstetrics and gynecology.

[75]  D. Painter Renal Disease: Classification and Atlas of Glomerular Diseases , 1996 .

[76]  E. Logigian,et al.  Neurological manifestations of primary Sjogren's syndrome. , 2010, Current opinion in neurology.

[77]  L. Magder,et al.  Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis , 2006, Lupus.

[78]  J. Yazdany,et al.  Systematic review of the literature informing the systemic lupus erythematosus indicators project: Reproductive health care quality indicators , 2011, Arthritis care & research.

[79]  W. Mccune,et al.  Should very low doses of hydroxychloroquine and quinacrine be employed in combination for long-term maintenance of remission in systemic lupus to reduce the risk of ocular toxicity? , 2015, Current opinion in rheumatology.

[80]  C. Ramos,et al.  Obesity and Cytokines in Childhood-Onset Systemic Lupus Erythematosus , 2014, Journal of immunology research.

[81]  J. Reveille,et al.  Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. , 2009, Arthritis and rheumatism.

[82]  Q. Nguyen,et al.  Faculty Opinions recommendation of Revised recommendations on screening for chloroquine and hydroxychloroquine retinopathy. , 2011 .

[83]  J. Sánchez-Guerrero,et al.  Menopause hormonal therapy in women with systemic lupus erythematosus. , 2007, Arthritis and rheumatism.

[84]  A. Reiff,et al.  Transition of Care and Health‐Related Outcomes in Pediatric‐Onset Systemic Lupus Erythematosus , 2015, Arthritis care & research.

[85]  B. Diamond,et al.  Pulse steroids: how much is enough? , 2006, Autoimmunity reviews.

[86]  E. Chakravarty,et al.  Herpes Zoster Vaccination in SLE: A Pilot Study of Immunogenicity , 2013, The Journal of Rheumatology.

[87]  G. Ruiz-Irastorza,et al.  Predictors of major infections in systemic lupus erythematosus , 2009, Arthritis research & therapy.

[88]  J. Ahearn,et al.  Erythrocyte C3d and C4d for monitoring disease activity in systemic lupus erythematosus. , 2010, Arthritis and rheumatism.

[89]  I. Bruce,et al.  Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort , 2014, Annals of the rheumatic diseases.

[90]  B. Rovin,et al.  Treatment of Lupus Nephritis With Abatacept: The Abatacept and Cyclophosphamide Combination Efficacy and Safety Study , 2014, Arthritis & rheumatology.

[91]  G. Hughes What causes lupus , 2009 .

[92]  J. Ioannidis,et al.  EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs , 2010, Annals of the rheumatic diseases.

[93]  A. Aggarwal,et al.  Childhood onset systemic lupus erythematosus: how is it different from adult SLE? , 2015, International journal of rheumatic diseases.

[94]  E. Morand,et al.  Definition and initial validation of a Lupus Low Disease Activity State (LLDAS) , 2015, Annals of the rheumatic diseases.

[95]  I. Bruce,et al.  Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort , 2016, Lupus Science & Medicine.

[96]  J. Piette,et al.  Importance of planning ovulation induction therapy in systemic lupus erythematosus and antiphospholipid syndrome: a single center retrospective study of 21 cases and 114 cycles. , 2002, Seminars in arthritis and rheumatism.

[97]  S. Pantovic,et al.  Late-onset systemic lupus erythematosus: clinical features, course, and prognosis , 2013, Clinical Rheumatology.

[98]  A. Rojas-Villarraga,et al.  Safety of Hormonal Replacement Therapy and Oral Contraceptives in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis , 2014, PloS one.

[99]  Christie M. Bartels,et al.  A systematic review and meta-analysis of cutaneous manifestations in late- versus early-onset systemic lupus erythematosus. , 2016, Seminars in arthritis and rheumatism.

[100]  K. Yancey,et al.  Differential expression of BAFF and its receptors in discoid lupus erythematosus patients. , 2014, Journal of dermatological science.

[101]  M. Petri,et al.  Baseline predictors of systemic lupus erythematosus flares: data from the combined placebo groups in the phase III belimumab trials. , 2013, Arthritis and rheumatism.

[102]  M. Petri,et al.  A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. , 2011, Arthritis and rheumatism.

[103]  C. Chambers,et al.  State of the art: Reproduction and pregnancy in rheumatic diseases. , 2015, Autoimmunity reviews.

[104]  J F Fries,et al.  The 1982 revised criteria for the classification of systemic lupus erythematosus. , 1982, Arthritis and rheumatism.

[105]  J. Reveille,et al.  Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L) , 2007, Annals of the rheumatic diseases.

[106]  D. Gladman,et al.  Optimal Monitoring For Coronary Heart Disease Risk in Patients with Systemic Lupus Erythematosus: A Systematic Review , 2016, The Journal of Rheumatology.

[107]  Virginia Pascual,et al.  Personalized Immunomonitoring Uncovers Molecular Networks that Stratify Lupus Patients , 2016, Cell.

[108]  J. James,et al.  Preclinical lupus , 2015, Current opinion in rheumatology.

[109]  H. Brunner,et al.  Update on differences between childhood-onset and adult-onset systemic lupus erythematosus , 2013, Arthritis Research & Therapy.

[110]  J. Craig,et al.  Diagnosis, Monitoring, and Treatment of Systemic Lupus Erythematosus: A Systematic Review of Clinical Practice Guidelines , 2015, Arthritis care & research.

[111]  I. Bruce,et al.  Prolonged remission in systemic lupus erythematosus. , 2005, The Journal of rheumatology.

[112]  G. Alarcón,et al.  Incomplete Systemic Lupus Erythematosus: Early Diagnosis or Overdiagnosis? , 2016, Arthritis care & research.

[113]  R. Sontheimer,et al.  Distinctive cutaneous subsets in the spectrum of lupus erythematosus. , 1981, Journal of the American Academy of Dermatology.

[114]  J. Pouchot,et al.  Adherence to treatment in systemic lupus erythematosus patients. , 2013, Best practice & research. Clinical rheumatology.

[115]  M. Maxwell,et al.  Azathioprine treatment of immunological renal disease. , 1967, JAMA.

[116]  K. Kalunian Interferon-targeted therapy in systemic lupus erythematosus: Is this an alternative to targeting B and T cells? , 2016, Lupus.

[117]  S. West,et al.  Reliability and validity of the proposed American College of Rheumatology neuropsychological battery for systemic lupus erythematosus. , 2004, Arthritis and rheumatism.

[118]  angesichts der Corona-Pandemie,et al.  UPDATE , 1973, The Lancet.

[119]  M. Aringer,et al.  Therapeutic blockade of TNF in patients with SLE-promising or crazy? , 2012, Autoimmunity reviews.

[120]  J. McDonagh,et al.  Adolescent rheumatology transition care in the UK. , 2012, Pediatric annals.

[121]  D. Solomon,et al.  Hydroxychloroquine improves insulin sensitivity in obese non-diabetic individuals , 2012, Arthritis Research & Therapy.

[122]  N. Senn,et al.  Development of a Comprehensive Approach for the Early Diagnosis of Geriatric Syndromes in General Practice , 2015, Front. Med..

[123]  B. Fessler,et al.  Alveolar hemorrhage in systemic lupus erythematosus: presentation and management. , 2000, Chest.

[124]  K. Schreiber Pregnancies in women with systemic lupus erythematosus and antiphospholipid antibodies , 2016, Lupus.

[125]  K. Costenbader,et al.  The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. , 2013, Seminars in arthritis and rheumatism.

[126]  G. Valesini,et al.  Flare, Persistently Active Disease, and Serologically Active Clinically Quiescent Disease in Systemic Lupus Erythematosus: A 2-Year Follow-Up Study , 2012, PloS one.

[127]  C. Cooper,et al.  Serum 25‐Hydroxyvitamin D Levels: Variability, Knowledge Gaps, and the Concept of a Desirable Range , 2015, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[128]  E. Bonfá,et al.  Impact of Therapy on Metabolic Syndrome in Young Adult Premenopausal Female Lupus Patients: Beneficial Effect of Antimalarials , 2015, Arthritis care & research.

[129]  J. Callen Management of "refractory" skin disease in patients with lupus erythematosus. , 2005, Best practice & research. Clinical rheumatology.

[130]  J. Singh,et al.  Risk of Herpes Zoster in Autoimmune and Inflammatory Diseases: Implications for Vaccination , 2016, Arthritis & rheumatology.

[131]  Frequency and determinants of flare and persistently active disease in systemic lupus erythematosus. , 2009, Arthritis and rheumatism.

[132]  J. Levy,et al.  Prospective observational single-centre cohort study to evaluate the effectiveness of treating lupus nephritis with rituximab and mycophenolate mofetil but no oral steroids , 2013, Annals of the rheumatic diseases.

[133]  Gideon P. Smith,et al.  Review of treatment for discoid lupus erythematosus , 2016, Dermatologic therapy.

[134]  R. Maciuca,et al.  A Phase II study of the efficacy and safety of rontalizumab (rhuMAb interferon-α) in patients with systemic lupus erythematosus (ROSE) , 2015, Annals of the rheumatic diseases.

[135]  L. Jara,et al.  Risk factors of systemic lupus erythematosus flares during pregnancy , 2014, Immunologic Research.

[136]  L. Arnaud,et al.  Late-Onset Systemic Lupus Erythematosus , 2012, Drugs & Aging.

[137]  L. Magder,et al.  Predictors of organ damage in systemic lupus erythematosus: the Hopkins Lupus Cohort. , 2012, Arthritis and rheumatism.